From 2020-2022, the biotech industry was the standout of the U.S. capital markets, thanks to the vital role the industry played in the Covid-19 pandemic response and the unprecedented capital investment that flowed into the industry for the diagnosis and treatment of all disease conditions. With that fresh capital, biotech companies leased millions of square […]
In an article published by The Boston Globe, industry experts, including our own Boston managing director, Nick Amarante, shared insights into the state of Boston’s biotech and life sciences industry, from layoffs to funding pullbacks and pipeline slowdowns. But the one underlying theme that deserves more attention is real estate. Vacancy is at record highs, tour volume is […]
Over two years ago, HM Science had forecast that a perfect storm was on the horizon for The Bay Area’s biotech wet lab market. That perfect storm would be comprised of 1) changes in the capital markets that would negatively affect demand, 2) growing wet lab sublease inventory and 3) record levels of new construction […]
Nick Amarante, executive vice president at Hughes Marino, co-founder of the Boston office and one of the founders of the company’s HM Science division, was featured in a Boston Globe article looking at the biotech slowdown in Boston and its impact on life science real estate. The frenzy of biotech investment during the COVID-19 pandemic […]
Life Science Cares leverages some of the most brilliant minds in the life science industry to take on one of the most important social issues of our time—poverty. Raising millions of dollars and tens of thousands of volunteer hours, with real-world, hands-on community support from its members, Life Science Cares’ mission is to provide immediate […]
In 2022, the Research Triangle region in Raleigh, Durham and Chapel Hill, North Carolina, was declared to be the fourth leading hub for biotech in the U.S., behind Boston, San Francisco and San Diego. Some of the biggest names in pharma have a presence there—including Novo Nordisk, Purdue Pharma, GSK, Merck, Amgen, Biogen and Pfizer—and […]
HM Science, the life science division of Hughes Marino, hosted two of the nation’s brightest minds in cancer research—Cigall Kadoch, Ph.D., Associate Professor of Medicine at the Dana-Farber Cancer Institute/Harvard Medical School and Investigator of the Howard Hughes Medical Institute, and Toni Choueiri, M.D., Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber […]
Cultivating a High-Performing Team Mindset Even coming face-to-face with a moose on a wooded trail while out on a winter run in Park City didn’t deter Owen Rice, executive vice president at Hughes Marino, from planning even more challenging and remote adventures. He’ll soon head to north central Washington to traverse 30 miles, summit two […]
When the COVID-19 pandemic hit, life science companies began attracting serious investment, hiring as fast as they could find talent, rushing to secure space to develop new drugs and vaccines and to manufacture medical equipment and supplies. Real estate investors, panicked over the rush to remote work and shuttering office space, quickly found an attractive […]
Nick Amarante, senior vice president of Hughes Marino, a founder of the Boston office, and one of the founders of the company’s HM Science division, is featured in a recent Boston Globe article looking at the biotech slowdown in Boston and its impact on life science real estate. The frenzy of biotech investment during the […]
